{
    "title": "109_hr5975",
    "content": "The \"Prescription Drug Comparative Effectiveness Act of 2006\" requires research and study on the effectiveness of certain prescription drugs. The \"Prescription Drug Comparative Effectiveness Act of 2006\" mandates research by the Agency for Healthcare Research and Quality to develop scientific evidence on the comparative clinical effectiveness, outcomes, and appropriateness of prescription drugs, medical devices, and procedures, with a focus on high volume, high cost, or high-risk treatments. This includes conducting systematic reviews of existing evidence. The Act mandates research on comparative clinical effectiveness, outcomes, and appropriateness of prescription drugs, medical devices, and procedures, with a focus on high volume, high cost, or high-risk treatments. The Secretary of Health and Human Services will develop a coordinated plan for research within 12 months. The Director of the Agency for Healthcare Research and Quality will prepare an annual report on research results related to measuring and comparing adverse events associated with pharmaceuticals and medical treatments. The report will be submitted to Congress, the Secretary of Defense, the Secretary of Health and Human Services, the Secretary of Veterans Affairs, and the Administrator of the Centers for Medicare & Medicaid Services. The Director of the Agency for Healthcare Research and Quality will prepare a report on systemic reviews for healthcare practitioners, identifying treatment options with insufficient evidence. The report will be shared with the Director of the National Institutes of Health and other research funding entities. The Director of the Agency for Healthcare Research and Quality will create easily understood versions of reports for patients receiving treatments. The Director will also publish reports online and make them accessible to the public in various formats to ensure accountability. The Department of Health and Human Services will publicly disclose scientific evidence and methodologies used in activities, allowing for evaluation and replication. $100,000,000 is authorized for fiscal year 2007, with additional funding for subsequent years."
}